Weight loss trials with white breast cancer survivors support the positive impact of weight loss on intermediate markers of breast cancer including sex hormones (estrogen, estradiol, testosterone, sex hormone binding globulin), chronic inflammation (C-reactive protein [CRP], interleukin-6 [IL-6], and TNF-α), and hyperinsulinemia (nsulin-like growth factor-1 [IGF-1], insulin-like growth binding protein-3 [IGBP3]). Here, IL6 is linked to hyperinsulinism.